Charles River Laboratories International, Inc. $CRL Stock: Diversified Trust Co Increases Position

Diversified Trust Co increased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 321.9% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 5,565 shares of the medical research company’s stock after buying an additional 4,246 shares during the period. Diversified Trust Co’s holdings in Charles River Laboratories International were worth $1,642,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of CRL. Aberdeen Group plc boosted its position in Charles River Laboratories International by 483.6% in the third quarter. Aberdeen Group plc now owns 792,576 shares of the medical research company’s stock worth $233,818,000 after purchasing an additional 656,777 shares during the last quarter. Amundi grew its stake in Charles River Laboratories International by 175.2% in the 1st quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after purchasing an additional 492,301 shares during the period. Russell Investments Group Ltd. grew its stake in Charles River Laboratories International by 457.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 436,055 shares of the medical research company’s stock valued at $128,641,000 after purchasing an additional 357,817 shares during the period. Dimensional Fund Advisors LP grew its stake in Charles River Laboratories International by 14.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after purchasing an additional 210,260 shares during the period. Finally, Assenagon Asset Management S.A. increased its position in shares of Charles River Laboratories International by 230.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 204,537 shares of the medical research company’s stock valued at $59,044,000 after purchasing an additional 142,716 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $338.27 on Monday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.41 and a quick ratio of 1.12. The business has a fifty day simple moving average of $311.21 and a two-hundred day simple moving average of $228.24. Charles River Laboratories International, Inc. has a 1 year low of $146.20 and a 1 year high of $379.63. The company has a market capitalization of $16.21 billion, a P/E ratio of 371.73, a P/E/G ratio of 3.05 and a beta of 1.36.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last issued its earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.97 by $0.12. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. The firm had revenue of $982.73 million for the quarter, compared to analyst estimates of $960.36 million. During the same period in the previous year, the company posted $2.43 earnings per share. The business’s revenue was down 2.2% on a year-over-year basis. On average, analysts expect that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current year.

Insider Activity at Charles River Laboratories International

In related news, Director James C. Foster sold 24,042 shares of the business’s stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $350.00, for a total value of $8,414,700.00. Following the sale, the director directly owned 31,596 shares in the company, valued at approximately $11,058,600. The trade was a 43.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total transaction of $163,442.52. Following the sale, the director directly owned 1,438 shares in the company, valued at approximately $410,175.12. This trade represents a 28.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 63,352 shares of company stock worth $20,291,281. Company insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CRL. CLSA cut Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 target price on the stock. in a research note on Monday, July 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Charles River Laboratories International in a report on Monday, September 28th. Royal Bank Of Canada increased their price target on shares of Charles River Laboratories International from $322.00 to $352.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. Barclays raised their price objective on shares of Charles River Laboratories International from $330.00 to $375.00 and gave the stock an “overweight” rating in a report on Thursday, November 5th. Finally, Morgan Stanley lifted their price objective on shares of Charles River Laboratories International from $300.00 to $340.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Thirteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $311.67.

Read Our Latest Analysis on Charles River Laboratories International

About Charles River Laboratories International

(Free Report)

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.

See Also

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.